Benny Sorensen, M.D., Ph.D., CEO, Hemab Therapeutics
Dr. Sorensen is CEO of Hemab Therapeutics, a privately held biotech company focused on rare bleeding and thrombosis disorders. Previously, Dr. Sorensen held several positions at Codiak, most recently as Senior Vice President, Strategic Projects and before that, SVP, Head of Clinical Development. Dr. Sorensen joined Codiak from Alnylam Pharmaceuticals, where he was Senior Director of Clinical Research since 2013 leading preclinical as well as clinical, regulatory, medical affairs and commercial development strategies for hematology products. He has more than 15 years of experience in clinical and translational research and management. Before joining Alnylam, Dr. Sorensen was a Global Medical Director at Baxter Healthcare Corporation advancing phase three pivotal development of Adynovate® and Vonvendi®. Prior to Baxter he was the Director of the Haemostasis Research Unit and Honorary Lecturer at Guy’s and St. Thomas’ Hospital & King’s College London School of Medicine, where he led basic translational research and advancement of several clinical trials across Phases I, II, and III. Dr. Sorensen has published extensively in hematology translational and clinical research.